NovoCure Limited (NVCR) Insider Yoram Palti Sells 8,000 Shares

NovoCure Limited (NASDAQ:NVCR) insider Yoram Palti sold 8,000 shares of the company’s stock in a transaction on Friday, May 12th. The shares were sold at an average price of $11.79, for a total value of $94,320.00. Following the completion of the sale, the insider now directly owns 63,825 shares in the company, valued at approximately $752,496.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Yoram Palti also recently made the following trade(s):

  • On Monday, June 5th, Yoram Palti sold 3,825 shares of NovoCure Limited stock. The shares were sold at an average price of $13.82, for a total value of $52,861.50.
  • On Friday, June 2nd, Yoram Palti sold 8,000 shares of NovoCure Limited stock. The shares were sold at an average price of $13.27, for a total value of $106,160.00.
  • On Wednesday, May 31st, Yoram Palti sold 8,000 shares of NovoCure Limited stock. The shares were sold at an average price of $12.49, for a total value of $99,920.00.
  • On Friday, May 26th, Yoram Palti sold 8,000 shares of NovoCure Limited stock. The shares were sold at an average price of $12.88, for a total value of $103,040.00.
  • On Wednesday, May 24th, Yoram Palti sold 4,000 shares of NovoCure Limited stock. The shares were sold at an average price of $13.15, for a total value of $52,600.00.
  • On Tuesday, May 23rd, Yoram Palti sold 8,000 shares of NovoCure Limited stock. The stock was sold at an average price of $11.73, for a total value of $93,840.00.
  • On Friday, May 19th, Yoram Palti sold 8,000 shares of NovoCure Limited stock. The stock was sold at an average price of $11.39, for a total value of $91,120.00.
  • On Wednesday, May 17th, Yoram Palti sold 4,000 shares of NovoCure Limited stock. The stock was sold at an average price of $11.47, for a total value of $45,880.00.
  • On Tuesday, May 16th, Yoram Palti sold 8,000 shares of NovoCure Limited stock. The stock was sold at an average price of $12.05, for a total value of $96,400.00.
  • On Wednesday, May 10th, Yoram Palti sold 8,000 shares of NovoCure Limited stock. The stock was sold at an average price of $12.29, for a total value of $98,320.00.

NovoCure Limited (NVCR) traded down 0.67% during midday trading on Friday, reaching $14.80. The company’s stock had a trading volume of 1,669,022 shares. The stock has a 50 day moving average of $12.78 and a 200 day moving average of $9.30. NovoCure Limited has a 52 week low of $5.95 and a 52 week high of $15.50. The firm’s market capitalization is $1.30 billion.

NovoCure Limited (NASDAQ:NVCR) last released its quarterly earnings data on Thursday, April 27th. The medical equipment provider reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.04. NovoCure Limited had a negative return on equity of 74.31% and a negative net margin of 109.30%. The company had revenue of $34.88 million for the quarter, compared to analyst estimates of $39.46 million. On average, equities research analysts predict that NovoCure Limited will post ($0.80) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for NovoCure Limited (NASDAQ:NVCR)

TRADEMARK VIOLATION WARNING: This article was originally published by Markets Daily and is the sole property of of Markets Daily. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://www.themarketsdaily.com/2017/06/16/novocure-ltd-nvcr-insider-yoram-palti-sells-8000-shares-of-stock-updated-updated-updated.html.

Large investors have recently added to or reduced their stakes in the stock. Flinton Capital Management LLC bought a new stake in NovoCure Limited during the fourth quarter valued at $111,000. Creative Planning raised its stake in NovoCure Limited by 32.1% in the first quarter. Creative Planning now owns 16,857 shares of the medical equipment provider’s stock valued at $137,000 after buying an additional 4,100 shares in the last quarter. American International Group Inc. raised its stake in NovoCure Limited by 7.1% in the first quarter. American International Group Inc. now owns 31,191 shares of the medical equipment provider’s stock valued at $253,000 after buying an additional 2,065 shares in the last quarter. Bank of America Corp DE raised its stake in NovoCure Limited by 61.7% in the first quarter. Bank of America Corp DE now owns 37,531 shares of the medical equipment provider’s stock valued at $305,000 after buying an additional 14,321 shares in the last quarter. Finally, Wedbush Securities Inc. bought a new stake in NovoCure Limited during the first quarter valued at $381,000. Institutional investors own 24.19% of the company’s stock.

A number of equities analysts have recently commented on the company. ValuEngine upgraded NovoCure Limited from a “sell” rating to a “hold” rating in a report on Saturday, June 3rd. Zacks Investment Research downgraded NovoCure Limited from a “buy” rating to a “hold” rating in a report on Wednesday, May 3rd. Wells Fargo & Company upgraded NovoCure Limited from a “market perform” rating to an “outperform” rating and set a $15.00 price objective on the stock in a report on Wednesday, May 24th. Deutsche Bank AG raised their target price on NovoCure Limited from $10.00 to $11.00 and gave the company a “hold” rating in a report on Friday, April 28th. Finally, J P Morgan Chase & Co reiterated a “buy” rating and set a $14.00 target price on shares of NovoCure Limited in a report on Monday, May 1st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $16.25.

NovoCure Limited Company Profile

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline.

Receive News & Ratings for NovoCure Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure Limited and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply